MCID: BCK001
MIFTS: 68

Becker Muscular Dystrophy malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Muscle diseases

Aliases & Classifications for Becker Muscular Dystrophy

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 27GTR, 31ICD10 via Orphanet, 35LifeMap Discovery®, 37MedGen, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Becker Muscular Dystrophy:

Name: Becker Muscular Dystrophy 52 35 11 48 24 54 70 12 13 68
Benign Pseudohypertrophic Muscular Dystrophy 11 48 68
Bmd 24 54 70
Muscular Dystrophy, Becker Type 48 27
Benign Congenital Myopathy 11 68
 
Becker Dystrophinopathy 48 54
Muscular Dystrophy Pseudohypertrophic Progressive, Becker Type 48
Becker's Muscular Dystrophy 48
Muscular Dystrophy Becker 50

Characteristics:

Orphanet epidemiological data:

54
becker muscular dystrophy:
Inheritance: X-linked recessive; Prevalence: 1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Italy),1-9/100000 (Egypt),1-9/1000000 (Japan),<1/1000000 (South Africa),1-9/100000 (Ireland),1-9/100000 (Puerto rico); Age of onset: Childhood; Age of death: any age

HPO:

64
becker muscular dystrophy:
Inheritance: x-linked recessive inheritance
Onset and clinical course: adult onset

Classifications:



External Ids:

OMIM52 300376
Disease Ontology11 DOID:9883
Orphanet54 ORPHA98895
MESH via Orphanet40 C537666
ICD10 via Orphanet31 G71.0
UMLS via Orphanet69 C0917713
MedGen37 C0917713
MeSH39 D020388

Summaries for Becker Muscular Dystrophy

About this section
OMIM:52 The muscular dystrophy that carries the Becker eponym is similar to Duchenne muscular dystrophy in the distribution of... (300376) more...

MalaCards based summary: Becker Muscular Dystrophy, also known as benign pseudohypertrophic muscular dystrophy, is related to duchenne muscular dystrophy and bethlem myopathy 1, and has symptoms including hyporeflexia, muscle weakness and cardiomyopathy. An important gene associated with Becker Muscular Dystrophy is DMD (Dystrophin), and among its related pathways are Agrin Interactions at Neuromuscular Junction and Smooth Muscle Contraction. Affiliated tissues include heart, skeletal muscle and testes, and related mouse phenotypes are growth/size/body region and skeleton.

NIH Rare Diseases:48 Becker muscular dystrophy (BMD) is an inherited condition that causes progressive weakness and wasting of the skeletal and cardiac (heart) muscles. It primarily affects males. The age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5 and 15. In some cases, heart involvement (cardiomyopathy) is the first sign. BMD is caused by a mutation in the DMD gene and is inherited in an X-linked recessive manner. BMD is very similar to Duchenne muscular dystrophy, except that in BMD, symptoms begin later and progress at a slower rate. There is no cure for this condition, but there is ongoing research that shows significant promise in treating the disease. Current treatment aims to relieve symptoms and improve quality of life. People with BMD may survive into their 40s or beyond. Last updated: 9/3/2016

UniProtKB/Swiss-Prot:70 Becker muscular dystrophy: A neuromuscular disorder characterized by dystrophin deficiency. It appears between the age of 5 and 15 years with a proximal motor deficiency of variable progression. Heart involvement can be the initial sign. Becker muscular dystrophy has a more benign course than Duchenne muscular dystrophy.

Related Diseases for Becker Muscular Dystrophy

About this section

Diseases related to Becker Muscular Dystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 76)
idRelated DiseaseScoreTop Affiliating Genes
1duchenne muscular dystrophy32.8DMD, GK
2bethlem myopathy 131.4DMD, DYSF
3muscular dystrophy, duchenne and becker type11.3
4muscular dystrophy11.2
5myotonia congenita, recessive11.0
6cardiomyopathy10.5
7d ercole syndrome10.5DMD, UTRN
8elane-related neutropenia10.4DMD, UTRN
9parkinsonism with spasticity, x-linked10.4DMD, GK
10cardiomyopathy, dilated, 3b10.4DMD, GK
11myopathy10.3
12leukemia, megakaryoblastic, with or without down syndrome, somatic10.3DMD, GK
13displacement of cardia through esophageal hiatus10.3DMD, NOS1
14cerebellar agenesis10.3DMD, DYSF
15hiatus hernia10.3DMD, NOS1
16colon cancer, advanced somatic10.3DMD, FKRP
17dilated cardiomyopathy10.3
18segawa syndrome, recessive10.2DMD, DYSF
19longitudinal vaginal septum10.2DMD, VCL
20myopathy, distal, 410.2DMD, DYSF
21spinal muscular atrophy10.2
22muscular atrophy10.2
23chronic granulomatous disease, x-linked10.2DMD, SGCA
24epilepsy, generalized, with febrile seizures plus, type 110.2DMD, VCL
25muscle hypertrophy10.1
26epilepsy10.1
27myositis10.1
28malignant hyperthermia10.1
29myotonic dystrophy10.1
30limb-girdle muscular dystrophy10.1
31microcephaly and chorioretinopathy 110.1DMD, DYSF
32klinefelter's syndrome10.0
33ischemia10.0
34myotonia10.0
35cubitus valgus with mental retardation and unusual facies10.0DMD, LAMA2
36muscular dystrophy-dystroglycanopathy , type b, 410.0DMD, LAMA2
37occupational dermatitis9.9DMD, UTRN
38schizophrenia9.9
39obesity9.9
40celiac disease9.9
41wolff-parkinson-white syndrome9.9
42angelman syndrome9.9
43glycerol kinase deficiency9.9
44inclusion body myositis9.9
45arthritis9.9
46liver disease9.9
47atrioventricular block9.9
48sleep apnea9.9
49lymphoma9.9
50cardiac arrest9.9

Graphical network of the top 20 diseases related to Becker Muscular Dystrophy:



Diseases related to becker muscular dystrophy

Symptoms & Phenotypes for Becker Muscular Dystrophy

About this section

Symptoms by clinical synopsis from OMIM:

300376

Clinical features from OMIM:

300376

Human phenotypes related to Becker Muscular Dystrophy:

 64 (show all 8)
id Description HPO Frequency HPO Source Accession
1 hyporeflexia64 HP:0001265
2 muscle weakness64 HP:0001324
3 cardiomyopathy64 HP:0001638
4 elevated serum creatine phosphokinase64 HP:0003236
5 myalgia64 HP:0003326
6 muscular dystrophy64 HP:0003560
7 calf muscle pseudohypertrophy64 HP:0003707
8 arrhythmia64 HP:0011675

UMLS symptoms related to Becker Muscular Dystrophy:


weakness

MGI Mouse Phenotypes related to Becker Muscular Dystrophy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053788.2DMD, FKRP, LAMA2, MYF6, NOS1, UTRN
2MP:00053907.8DMD, FKRP, LAMA2, MYF6, NOS1, UTRN
3MP:00053767.3DMD, DYSF, FKRP, LAMA2, MYF6, NOS1
4MP:00053696.9DMD, DYSF, FKRP, LAMA2, MYF6, NOS1

Drugs & Therapeutics for Becker Muscular Dystrophy

About this section

Drugs for Becker Muscular Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 203)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Carvedilolapproved, investigationalPhase 416372956-09-32585
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
107741-96-8
72956-09-3
AB1004830
AC-1641
AC1L1E0B
Artist
Artist (TN)
Atlana Pharma brand of carvedilol
BM 14190
BM-14-190
BM-14.190
BM-14190
BRD-A10977446-001-04-8
BRD-A10977446-045-01-1
Bio-0014
C043211
C06875
C2260
C24H26N2O4
CHEBI:3441
CHEMBL723
CID2585
CPD000449280
Carvedilol
Carvedilol (JAN/USAN/INN)
Carvedilol [USAN:INN:BAN:JAN]
Carvedilolum
Carvedilolum [Latin]
Coreg
Coreg (TN)
Coreg CR
Coropres
Coropress
D00255
DB01136
DQ 2466
DQ-2466
Dibloc
 
Dilatrend
EG-P042
Eucardic
GlaxoSmithKline brand of carvedilol
HMS2051N03
HMS2089B09
HMS2093E12
HSDB 7044
I06-0064
I06-1477
KBio2_002145
KBio2_004713
KBio2_007281
KBio3_002323
KBioGR_001252
KBioSS_002145
Kredex
L001243
LS-121875
Lakeside brand of carvedilol
MLS000758299
MLS000759508
MLS001424092
MolPort-003-666-814
NCGC00167832-01
NCGC00167832-02
NCGC00167832-03
Querto
Roche brand of carvedilol
SAM001246736
SAM001247021
SK&F-105517
SKF 105517
SMR000449280
SPBio_001885
STK621453
Spectrum2_001673
Spectrum3_001182
Spectrum4_000636
Spectrum5_001436
Spectrum_001665
TL8005080
UNII-0K47UL67F2
carvedilol
carvedilol, (+-)-isomer
carvedilol, (R)-isomer
carvedilol, (S)-isomer
carvedilol, 14C-labeled
2
RamiprilapprovedPhase 415187333-19-55362129
Synonyms:
(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)
(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic
(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p
(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
126613-39-6
87333-19-5
AC-1347
AC1NSFPR
Acovil
Almirall Brand of Ramipril
Altace
Altace (TN)
Altace (tn)
Astra Brand of Ramipril
AstraZeneca Brand of Ramipril
Aventis Brand of Ramipril
Aventis Pharma Brand of Ramipril
BIDD:GT0803
BSPBio_003347
Bio-0651
C23H32N2O5
CHEBI:289203
CHEBI:8774
CHEMBL1168
CID5362129
CPD000466386
Carasel
Cardace
D00421
D017257
DB00178
Delix
HMS2051E04
HMS2090L11
HMS2093M10
HOE 498
HOE498
Hoe-498
Hoechst Brand of Ramipril
 
Hypren
Hytren
KBio2_002504
KBio2_005072
KBio2_007640
KBio3_002849
KBioGR_001858
KBioSS_002512
LS-58199
Lostapres
MLS000759523
MLS001216547
MLS001423965
MolPort-001-736-571
Monarch Brand of Ramipril
N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid
NCGC00178127-01
Naprix
Pramace
Pramace (discontinued)
Promed Brand of Ramipril
Quark
R0404_SIGMA
Ramace
Ramipril
Ramipril (USP/INN)
Ramipril [USAN:INN:BAN]
Ramiprilum
Ramiprilum [Latin]
Ramipro, Tritace, Altace, Prilace, Ramipril
S1793_Selleck
SAM001246757
SAM002699899
SMR000466386
SPECTRUM1505214
STK801937
Spectrum3_001794
Spectrum4_001269
Spectrum5_001721
Spectrum_001958
Triatec
Tritace
UNII-L35JN3I7SJ
Unipril
Vesdil
Zabien
[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
ramipril
3
Tadalafilapproved, investigationalPhase 4, Phase 3, Phase 1149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
4HIV Protease InhibitorsPhase 4, Phase 3, Phase 25319
5Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
6
protease inhibitorsPhase 4, Phase 3, Phase 25320
Synonyms:
 
protease inhibitors
7Adrenergic AgentsPhase 4, Phase 35140
8Vasodilator AgentsPhase 4, Phase 3, Phase 2, Phase 13438
9Adrenergic alpha-1 Receptor AntagonistsPhase 4470
10Antihypertensive AgentsPhase 4, Phase 3, Phase 24095
11Adrenergic AntagonistsPhase 41535
12Adrenergic beta-AntagonistsPhase 41154
13Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2711
14Adrenergic alpha-AntagonistsPhase 4727
15Anti-Bacterial AgentsPhase 4, Phase 2, Phase 110884
16Phosphodiesterase 5 InhibitorsPhase 4, Phase 3, Phase 2, Phase 1571
17Phosphodiesterase InhibitorsPhase 4, Phase 3, Phase 2, Phase 11254
18Antibiotics, AntitubercularPhase 46972
19
MetforminapprovedPhase 3, Phase 2, Phase 11746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
20Idebenoneapproved, investigationalPhase 3, Phase 22158186-27-9
21
Enalaprilapproved, vet_approvedPhase 312075847-73-35362032, 40466924
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
75847-73-3
AC1NTUS5
Analapril
BIDD:GT0751
BPBio1_000340
BSPBio_000308
BSPBio_003035
Bonuten
C06977
CAS-76095-16-4
CHEBI:116847
CHEBI:4784
CHEMBL578
CID5388962
D07892
DivK1c_000408
Enalapril
Enalapril (INN)
Enalapril (TN)
Enalapril Bp
Enalapril Maleate
Enalapril Richet
Enalaprila
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
 
Enalaprilum [INN-Latin]
Gadopril
HMS2090E08
IDI1_000408
KBio1_000408
KBio2_001787
KBio2_004355
KBio2_006923
KBio3_002535
KBioGR_000355
KBioSS_001787
Kinfil
LS-190651
MolPort-002-885-877
N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline
N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline
NCGC00016932-01
NCGC00021569-04
NCGC00021569-05
NCGC00021569-06
NINDS_000408
Prestwick3_000314
SPBio_001349
Spectrum2_001455
Spectrum3_001478
Spectrum4_000008
Spectrum5_001107
Spectrum_001307
Vaseretic
Vasotec
Vasotec IV
enalapril
22
SpironolactoneapprovedPhase 32221952-01-7, 52-01-75833
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
496916-40-6
52-01-7
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
AB00513806
AC-4214
AC1L1L8Q
Abbolactone
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm Brand of Spironolactone
Alpharma Brand of Spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne Brand of Spironolactone
Azupharma Brand of Spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
Cardel Brand of Spironolactone
D00443
D013148
DB00421
Deverol
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona Alter
Espironolactona Mundogen
Espironolactona [INN-Spanish]
Euteberol
Flumach
Frumikal
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
HSDB 3184
Hormosan Brand of Spironolactone
I06-1970
Jenapharm Brand of Spironolactone
Jenaspiron
LS-118614
LT00772287
Lacalmin
Lacdene
Laractone
MLS001074672
MLS001333253
MLS001333254
MLS002153245
MLS002207058
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura Brand of Spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
 
NCGC00164397-02
NSC 150399
NSC150399
Nefurofan
Novo Spiroton
Novo-Spiroton
NovoSpiroton
Novopharm Brand of Spironolactone
Osyrol
Pfizer Brand of Spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche Brand of Spironolactone
S0260
S3378_SIGMA
SAM002264648
SC 9420
SC-9420
SC9420
SMR000471892
SNL
SPBio_002115
Sagisal
Searle Brand of Spironolactone
Sincomen
Spiractin
Spiresis
Spiretic
Spiridon
Spiro L.U.T.
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro-Tablinen
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono Isis
Spirono-Isis
Spironocompren
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone A
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Xenalon
ZINC03861599
betapharm Brand of Spironolactone
ct Arzneimittel Brand of Spironolactone
ct-Arzneimittel Brand of Spironolactone
spiro von ct
spironolactone
spironolattone
von ct, spiro
23
Lisinoprilapproved, investigationalPhase 2, Phase 311883915-83-75362119
Synonyms:
(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline
76547-98-3
77726-95-5
83915-83-7 (Parent)
AC1NSFPF
Acerbon
Acercomp
Alapril
BB_NC-1454
BIDD:GT0755
BPBio1_000290
BRD-K67966701-335-03-5
BRN 4276619
BSPBio_000262
C21H31N3O5
CCRIS 3568
CHEBI:43755
CHEMBL1237
CID5362119
Carace
Cipral
Cipril
Coric
D08131
DB00722
DivK1c_001037
Doneka
EINECS 278-488-1
HMS1921B14
HMS2090O14
HMS2092L21
HMS503O15
I06-1895
ICI-209K
IDI1_001037
Inhibril
Inopril
KBio1_001037
KBio2_000977
KBio2_003545
KBio2_006113
KBio3_002002
KBioGR_001599
KBioSS_000977
L0220
LPR
LS-118899
Linopril
Linvas
Lipril
Lisinal
 
Lisinopril
Lisinopril (INN)
Lisinopril (anhydrous)
Lisinopril Dihydrate
Lisinopril anhydrous
Lisinoprilum
Lisinoprilum [Latin]
Lisipril
Lisoril
Lispril
Longes
Loril
Lysinopril
MK 521
MK 522
MK-521
MLS001306436
MLS001306481
MolPort-002-507-428
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
NCGC00179623-01
NINDS_001037
Noperten
Novatec
Presiten
Prestwick0_000301
Prestwick1_000301
Prestwick2_000301
Prestwick3_000301
Prinil
Prinivil
Prinzide
Renacor
SMR000544473
SPBio_001351
SPBio_002481
SPECTRUM1501217
Sinopril
Sinopryl
Spectrum2_001456
Spectrum3_000941
Spectrum4_001040
Spectrum5_000995
Spectrum_000497
TL8005499
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
Zestril (TN)
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
lisinopril
24
EplerenoneapprovedPhase 394107724-20-9150310, 443872
Synonyms:
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
AC-4213
AC1L9FDC
C12512
CGP-30083
CHEBI:31547
CHEBI:726453
CHEMBL1095097
CID443872
D01115
Eplerenone
 
Eplerenone (JAN/USAN/INN)
Epoxymexrenone
Inspra
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
MolPort-003-986-216
NCGC00159559-01
NCGC00159559-02
S1707_Selleck
SC-66110
Selara
TL8000270
ZINC03985982
25
Prednisoneapproved, vet_approvedPhase 3, Phase 2135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
26
EnalaprilatapprovedPhase 312076420-72-96917719
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate
1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
76420-72-9
AC1NUWEA
AC1OCEK7
BIDD:GT0752
C11720
C18H24N2O5.2H2O
CHEBI:116759
CHEBI:42302
CHEBI:4786
CHEBI:59877
CHEMBL1200697
CHEMBL577
CID5462501
CID6917719
CPD000466359
D03769
EAL
ENALAPRILAT INHIBITOR
Enalapril acid
Enalapril diacid
Enalaprilat
Enalaprilat (USP)
 
Enalaprilat anhydrous
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalprilate hydrate
HMS2051H16
HMS2089P04
LS-118903
LS-187219
MK-422
MLS000759476
MLS001424138
MolPort-005-943-792
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline--water (1/2)
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline—water (1/2)
NCGC00164593-01
S1657_Selleck
SAM001246684
SBB065733
SMR000466359
Vasotec I.V.
enalaprilat dihydrate
enalaprilat hydrate
enalprilat hydrate
enalprilate hydrate
27
BenzocaineapprovedPhase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
28
Zoledronic acidapprovedPhase 3290118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
29
Nebivololapproved, investigationalPhase 382152520-56-4, 99200-09-6, 118457-14-071301
Synonyms:
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
104365-59-5
118457-14-0
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
99200-09-6
AC-1611
AC1L2FX8
AC1Q4OMF
Bystolic
C22H25F2NO4
CHEMBL434394
CID71301
D05127
DB04861
I06-0378
L001284
LS-178404
Lobivon
MolPort-003-849-343
Narbivolol
 
Nebicard-5
Nebilet
Nebilong
Nebipill
Nebivolol
Nebivolol (USAN/INN)
Nebivolol [USAN:INN:BAN]
Nebivololum
Nebivololum [Latin]
Nebivololum [latin]
Nubeta
PDSP1_000244
PDSP2_000243
PI-21858
R 67555
R-67555
R65,824
UNII-030Y90569U
alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol)
alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
30
Creatineapproved, nutraceuticalPhase 2, Phase 312657-00-1586
Synonyms:
((amino(Imino)methyl)(methyl)amino)acetic acid
((amino(imino)methyl)(methyl)amino)acetate
((amino(imino)methyl)(methyl)amino)acetic acid
(N-methylcarbamimidamido)acetic acid
(alpha-Methylguanido)acetate
(alpha-Methylguanido)acetic acid
(α-methylguanido)acetic acid
Cosmocair C 100
Creatin
Creatine
Creatine hydrate
Kreatin
 
Krebiozon
Methylglycocyamine
Methylguanidoacetate
Methylguanidoacetic acid
N-(Aminoiminomethyl)-N-Methyl-Glycine
N-(aminoiminomethyl)-N-methylglycine
N-Amidinosarcosine
N-Carbamimidoyl-N-methylglycine
N-Methyl-N-guanylglycine
N-[(e)-AMINO(imino)methyl]-N-methylglycine
Phosphagen
[[Amino(imino)methyl](methyl)amino]acetate
[[Amino(imino)methyl](methyl)amino]acetic acid
alpha-Methylguanidino acetic acid
31tannic acidapproved, NutraceuticalPhase 31892
32diureticsPhase 3, Phase 11372
33Bone Density Conservation AgentsPhase 3, Phase 13266
34Anti-Inflammatory AgentsPhase 3, Phase 2, Phase 110355
35Natriuretic AgentsPhase 3, Phase 11645
36Hypoglycemic AgentsPhase 3, Phase 2, Phase 15733
37Antineoplastic Agents, HormonalPhase 3, Phase 2, Phase 15407
38Immunosuppressive AgentsPhase 3, Phase 112770
39Adrenergic AgonistsPhase 32877
40VitaminsPhase 2, Phase 35095
41Pharmaceutical SolutionsPhase 3, Phase 2, Phase 17793
42AntioxidantsPhase 3, Phase 2, Phase 12928
43DeflazacortPhase 3, Phase 11314484-47-0
44MineralocorticoidsPhase 3352
45Trace ElementsPhase 3, Phase 25802
46UbiquinonePhase 3, Phase 2139
47Protective AgentsPhase 3, Phase 2, Phase 17190
48MicronutrientsPhase 3, Phase 25802
49Hormone AntagonistsPhase 3, Phase 2, Phase 112778
50Mineralocorticoid Receptor AntagonistsPhase 3333

Interventional clinical trials:

(show top 50)    (show all 199)
idNameStatusNCT IDPhase
1Ramipril Versus Carvedilol in Duchenne and Becker PatientsUnknown statusNCT00819845Phase 4
2The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular DystrophyUnknown statusNCT00606775Phase 4
3Tadalafil in Becker Muscular DystrophyCompletedNCT01070511Phase 4
4PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular DystrophyCompletedNCT02207283Phase 4
5Stacking Exercises Aid the Decline in FVC and Sick TimeActive, not recruitingNCT01999075Phase 4
6Effects of Sodium Nitrate on Blood Flow in Becker Muscular DystrophyUnknown statusNCT02147639Phase 2, Phase 3
7Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)CompletedNCT00592553Phase 2, Phase 3
8High-dose Prednisone in Duchenne Muscular DystrophyCompletedNCT00110669Phase 3
9Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy TrialCompletedNCT02432885Phase 3
10L-citrulline and Metformin in Duchenne's Muscular DystrophyCompletedNCT01995032Phase 3
11Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular DystrophyCompletedNCT00004646Phase 3
12A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular DystrophyCompletedNCT01254019Phase 3
13Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)CompletedNCT01027884Phase 3
14Creatine and Glutamine in Steroid-Naive Duchenne Muscular DystrophyCompletedNCT00016653Phase 2, Phase 3
15A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)CompletedNCT00018109Phase 3
16Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular DystrophyCompletedNCT01826487Phase 3
17Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyRecruitingNCT02354352Phase 3
18A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid SteroidsRecruitingNCT02814019Phase 3
19Confirmatory Study of Eteplirsen in DMD PatientsRecruitingNCT02255552Phase 3
20Study of SRP-4045 and SRP-4053 in DMD PatientsRecruitingNCT02500381Phase 3
211 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With GlucocorticoidsRecruitingNCT01197300Phase 3
22A Research Study of Zoledronic Acid in Children and Adolescents With OsteoporosisRecruitingNCT00799266Phase 3
23Finding the Optimum Regimen for Duchenne Muscular DystrophyActive, not recruitingNCT01603407Phase 3
24Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyActive, not recruitingNCT01183767Phase 2, Phase 3
25Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyActive, not recruitingNCT01648634Phase 3
26Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaActive, not recruitingNCT01557400Phase 3
27Study of Ataluren for Previously Treated Patients With nmDBMD in the USEnrolling by invitationNCT01247207Phase 3
28Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesEnrolling by invitationNCT01126697Phase 2, Phase 3
29Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation DystrophinopathyEnrolling by invitationNCT02090959Phase 3
30Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyNot yet recruitingNCT02851797Phase 3
31Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)TerminatedNCT00847379Phase 2, Phase 3
32A Study of Tadalafil for Duchenne Muscular DystrophyTerminatedNCT01865084Phase 3
33Extension Study of Drisapersen in DMD SubjectsTerminatedNCT02636686Phase 3
34CoQ10 and Prednisone in Non-Ambulatory DMDTerminatedNCT00308113Phase 3
35Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyTerminatedNCT01480245Phase 3
36A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian SubjectsTerminatedNCT01803412Phase 3
37Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular DisordersTerminatedNCT00839033Phase 3
38Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment ProtocolWithdrawnNCT01890798Phase 3
39Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)Unknown statusNCT01856868Phase 1, Phase 2
40Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular DystrophyUnknown statusNCT02285673Phase 1, Phase 2
41Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular DystrophyUnknown statusNCT01610440Phase 1, Phase 2
42Safety and Efficacy Study of IGF-1 in Duchenne Muscular DystrophyUnknown statusNCT01207908Phase 1, Phase 2
43Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular DystrophyUnknown statusNCT01834040Phase 1, Phase 2
44Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.Unknown statusNCT01834066Phase 1, Phase 2
45L-citrulline and Metformin in Becker's Muscular DystrophyCompletedNCT02018731Phase 2
46CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic CarriersCompletedNCT01540604Phase 2
47Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy PatientsCompletedNCT01350154Phase 2
48Safety and Efficacy Study of PTC124 in Duchenne Muscular DystrophyCompletedNCT00264888Phase 2
49Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular DystrophyCompletedNCT00159250Phase 1, Phase 2
50Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular DystrophyCompletedNCT00654784Phase 2

Search NIH Clinical Center for Becker Muscular Dystrophy

Genetic Tests for Becker Muscular Dystrophy

About this section

Genetic tests related to Becker Muscular Dystrophy:

id Genetic test Affiliating Genes
1 Becker Muscular Dystrophy27 24

Anatomical Context for Becker Muscular Dystrophy

About this section

MalaCards organs/tissues related to Becker Muscular Dystrophy:

36
Heart, Skeletal muscle, Testes, Bone, Brain, Cortex, Liver

Publications for Becker Muscular Dystrophy

About this section

Articles related to Becker Muscular Dystrophy:

(show top 50)    (show all 523)
idTitleAuthorsYear
1
Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis or GNE myopathy. (28042944)
2017
2
Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Confirmed by Multiplex Ligation-Dependent Probe Amplification: Genotype-Phenotype Correlation in a Large Cohort. (28079318)
2017
3
Extensive Functional Evaluations to Monitor Aerobic Training in Becker Muscular Dystrophy: A Case Report. (27478558)
2016
4
Genetic and Early Clinical Manifestations of Females Heterozygous for Duchenne/Becker Muscular Dystrophy. (26718981)
2016
5
A case report: Becker muscular dystrophy presenting with epilepsy and dysgnosia induced by duplication mutation of Dystrophin gene. (27955624)
2016
6
Left ventricular hypertrophy: A rare cardiac involvement of Becker muscular dystrophy. (27742039)
2016
7
Consecutive analysis of mutation spectrum in the dystrophin gene of 507 Korean boys with Duchenne/Becker muscular dystrophy in a single center. (27593222)
2016
8
The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study. (27209345)
2016
9
Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies. (26974331)
2016
10
Guidelines for the Perianesthesia Care of the Duchenne Muscular Dystrophy/Becker Muscular Dystrophy Patient. (27931703)
2016
11
Cardiomyopathy in becker muscular dystrophy: Overview. (27354892)
2016
12
Cardiac involvement in female carriers of Duchenne or Becker muscular dystrophy. (27761893)
2016
13
Therapeutic Strategy for Heart Failure in Becker Muscular Dystrophy. (27593540)
2016
14
Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. (26911353)
2016
15
Knowledge of carrier status and barriers to testing among mothers of sons with Duchenne or Becker muscular dystrophy. (27863875)
2016
16
Dystrophin Hot-Spot Mutants Leading to Becker Muscular Dystrophy Insert More Deeply into Membrane Models than the Native Protein. (27367833)
2016
17
Errata: Therapeutic Strategy for Heart Failure in Becker Muscular Dystrophy. (27916789)
2016
18
A Novel Mutation in DMD (c.10797+5G>A) Causes Becker Muscular Dystrophy Associated with Intellectual Disability. (26836830)
2016
19
A Case of Refractory Heart Failure in Becker Muscular Dystrophy Improved With Corticosteroid Therapy. (27535714)
2016
20
Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. (27582364)
2016
21
Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. (27485237)
2016
22
Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet. (26966795)
2016
23
Evaluation of point mutations in dystrophin gene in Iranian Duchenne and Becker muscular dystrophy patients: introducing three novel variants. (27350676)
2016
24
Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I. (27463532)
2016
25
Prevalence and Genetic Profile of Duchene and Becker Muscular Dystrophy in Puerto Rico. (27854217)
2016
26
Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy. (26966800)
2016
27
Becker muscular dystrophy due to an intronic splicing mutation inducing a dual dystrophin transcript. (27616544)
2016
28
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. (27926769)
2016
29
Diagnosis of Becker muscular dystrophy: Results of re-analysis of DNA samples. (25900853)
2015
30
Life-threatening Arrhythmias in a Becker Muscular Dystrophy Family due to the Duplication of Exons 3-4 of the Dystrophin Gene. (26631896)
2015
31
Abnormal short-latency synaptic plasticity in the motor cortex of subjects with Becker muscular dystrophy: a rTMS study. (26562314)
2015
32
Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. (26295289)
2015
33
Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies. (26042512)
2015
34
Response to: Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity. (26004424)
2015
35
Pain in adolescents with spinal muscular atrophy and Duchenne and Becker muscular dystrophy. (25978940)
2015
36
Mothers' psychological adaptation to Duchenne/Becker muscular dystrophy. (26306645)
2015
37
A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China. (25612904)
2015
38
Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members. (25647308)
2015
39
Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study. (26113120)
2015
40
Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient. (26247048)
2015
41
Obesity and Premature Loss of Mobility in Two Adolescents with Becker Muscular Dystrophy Following HeartMate II Implantation. (26461240)
2015
42
Cardiac involvement in Duchenne and Becker muscular dystrophy. (26225202)
2015
43
TNF-I+-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. (26321630)
2015
44
Early-progressive dilated cardiomyopathy in a family with Becker muscular dystrophy related to a novel frameshift mutation in the dystrophin gene exon 27. (25537791)
2015
45
Evidence of Insulin Resistance and Other Metabolic Alterations in Boys with Duchenne or Becker Muscular Dystrophy. (26089900)
2015
46
Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. (26022172)
2015
47
Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy. (26437761)
2015
48
Health services received by individuals with Duchenne/Becker muscular dystrophy. (26044770)
2015
49
Late-onset Becker muscular dystrophy: Refining the clinical features and electrophysiological findings. (26179421)
2015
50
Leptin and metabolic syndrome in patients with Duchenne/Becker muscular dystrophy. (26133644)
2015

Variations for Becker Muscular Dystrophy

About this section

UniProtKB/Swiss-Prot genetic disease variations for Becker Muscular Dystrophy:

70
id Symbol AA change Variation ID SNP ID
1DMDp.Ala168AspVAR_005149
2DMDp.Tyr231AsnVAR_005150
3DMDp.His2921ArgVAR_005170rs1800279
4DMDp.Ala3421ValVAR_005172
5DMDp.Ala171ProVAR_023539

Clinvar genetic disease variations for Becker Muscular Dystrophy:

5 (show all 183)
id Gene Variation Type Significance SNP ID Assembly Location
1DMDNM_004006.2(DMD): c.8944C> T (p.Arg2982Ter)SNVPathogenicrs128625229GRCh37Chr X, 31462738: 31462738
2DMDNM_004006.2(DMD): c.10108C> T (p.Arg3370Ter)SNVPathogenicrs104894787GRCh37Chr X, 31196901: 31196901
3DMDNM_004006.2(DMD): c.433C> T (p.Arg145Ter)SNVPathogenicrs128626235GRCh37Chr X, 32834682: 32834682
4DMDDMD, IVS19, A-C, +3SNVPathogenicChr na, -1: -1
5DMDDMD, IVS57, G-C, -1SNVPathogenicChr na, -1: -1
6DMDNM_004006.2(DMD): c.503C> A (p.Ala168Asp)SNVPathogenicrs128626236GRCh37Chr X, 32834612: 32834612
7DMDDMD, IVS2, G-T, -1SNVPathogenicChr na, -1: -1
8DMDNM_004006.2(DMD): c.691T> A (p.Tyr231Asn)SNVPathogenicrs128626237GRCh37Chr X, 32717369: 32717369
9DMDBMD, IVS13, G-T, -1SNVPathogenicChr na, -1: -1
10DMDNM_004006.2(DMD): c.5899C> T (p.Arg1967Ter)SNVPathogenicrs128626249GRCh37Chr X, 32360240: 32360240
11DMDNM_004006.2(DMD): c.6373C> T (p.Gln2125Ter)SNVPathogenicrs128626251GRCh37Chr X, 32235098: 32235098
12DMDNM_004006.2(DMD): c.10262C> T (p.Ala3421Val)SNVPathogenicrs104894791GRCh37Chr X, 31196049: 31196049
13DMDDMD, 1-BP DEL, 10683CdeletionPathogenicChr na, -1: -1
14DMDNM_004006.2(DMD): c.3631G> T (p.Glu1211Ter)SNVPathogenicrs267606771GRCh37Chr X, 32466728: 32466728
15DMDNM_004006.2(DMD): c.9568C> T (p.Arg3190Ter)SNVPathogenicrs104894797GRCh37Chr X, 31224780: 31224780
16DMDNM_004006.2(DMD): c.3940C> T (p.Arg1314Ter)SNVPathogenicrs5030730GRCh37Chr X, 32456489: 32456489
17DMDNM_004006.2(DMD): c.9225-285A> GSNVPathogenicrs587776747GRCh37Chr X, 31279418: 31279418
18DMDDMD, IVS25, A-G, +2036SNVPathogenicChr na, -1: -1
19DMDNM_004006.2(DMD): c.8713C> T (p.Arg2905Ter)SNVPathogenicrs128627256GRCh37Chr X, 31496447: 31496447
20DMDNM_004006.2(DMD): c.1812+1G> ASNVLikely pathogenic, Pathogenicrs373286166GRCh37Chr X, 32591646: 32591646
21DMDNM_004006.2(DMD): c.9164-1G> CSNVPathogenicrs398124082GRCh37Chr X, 31341776: 31341776
22DMDNM_004006.2(DMD): c.8680G> T (p.Glu2894Ter)SNVPathogenicrs727503802GRCh37Chr X, 31496480: 31496480
23DMDNM_004006.2(DMD): c.5363C> G (p.Ser1788Ter)SNVPathogenicrs199774535GRCh37Chr X, 32366608: 32366608
24DMDNM_004006.2(DMD): c.4806A> T (p.Gly1602=)SNVPathogenicrs727503830GRCh37Chr X, 32398666: 32398666
25DMDNM_004006.2(DMD): c.3532G> T (p.Glu1178Ter)SNVPathogenicrs727503836GRCh38Chr X, 32454733: 32454733
26DMDNM_004006.2(DMD): c.2956C> T (p.Gln986Ter)SNVPathogenicrs727503844GRCh37Chr X, 32486821: 32486821
27DMDNM_004006.2(DMD): c.2755A> T (p.Lys919Ter)SNVPathogenicrs727503850GRCh38Chr X, 32484967: 32484967
28DMDNM_004006.2(DMD): c.2484T> G (p.Tyr828Ter)SNVPathogenicrs727503858GRCh37Chr X, 32509532: 32509532
29DMDNM_004006.2(DMD): c.883C> T (p.Arg295Ter)SNVPathogenicrs727503864GRCh38Chr X, 32697947: 32697947
30DMDNM_004006.2(DMD): c.14_15delAAinsT (p.Glu5Valfs)indelPathogenicrs796065325GRCh37Chr X, 33229415: 33229416
31DMDNM_004006.2(DMD): c.1093C> T (p.Gln365Ter)SNVPathogenicrs794726993GRCh37Chr X, 32663137: 32663137
32DMDNM_004006.2(DMD): c.1070delC (p.Ser357Leufs)deletionPathogenicrs794726994GRCh37Chr X, 32663160: 32663160
33DMDNM_004006.2(DMD): c.1286C> G (p.Ser429Ter)SNVPathogenicrs398123853GRCh37Chr X, 32662294: 32662294
34DMDNM_004006.2(DMD): c.1150-2A> GSNVPathogenicrs794727030GRCh37Chr X, 32662432: 32662432
35DMDNM_004006.2(DMD): c.1533_1536delTCAC (p.His512Trpfs)deletionPathogenicrs794727097GRCh37Chr X, 32613940: 32613943
36DMDNM_004006.2(DMD): c.1704+1G> ASNVPathogenicrs794727123GRCh37Chr X, 32591861: 32591861
37DMDNM_004006.2(DMD): c.1912C> T (p.Gln638Ter)SNVPathogenicrs794727170GRCh37Chr X, 32583899: 32583899
38DMDNM_004006.2(DMD): c.2601_2602delAA (p.Gln869Valfs)deletionPathogenicrs794727322GRCh37Chr X, 32509414: 32509415
39DMDNM_004006.2(DMD): c.2479G> T (p.Glu827Ter)SNVPathogenicrs794727323GRCh37Chr X, 32509537: 32509537
40DMDNM_004006.2(DMD): c.2803+1G> CSNVPathogenicrs398123908GRCh37Chr X, 32503035: 32503035
41DMDNM_004006.2(DMD): c.2804-2A> TSNVPathogenicrs794727357GRCh37Chr X, 32490428: 32490428
42DMDNM_004006.2(DMD): c.2815_2816delTT (p.Leu939Alafs)deletionPathogenicrs794727358GRCh37Chr X, 32490414: 32490415
43DMDNM_004006.2(DMD): c.2933_2934delGA (p.Arg978Thrfs)deletionPathogenicrs794727359GRCh37Chr X, 32490296: 32490297
44DMDNM_004006.2(DMD): c.3497_3500delTATC (p.Leu1166Glnfs)deletionPathogenicrs794727421GRCh37Chr X, 32472882: 32472885
45DMDNM_004006.2(DMD): c.3535G> T (p.Glu1179Ter)SNVPathogenicrs794727422GRCh37Chr X, 32472847: 32472847
46DMDNM_004006.2(DMD): c.3838A> T (p.Lys1280Ter)SNVPathogenicrs794727463GRCh37Chr X, 32459380: 32459380
47DMDNM_004006.2(DMD): c.133C> T (p.Gln45Ter)SNVPathogenicrs794727499GRCh38Chr X, 32849781: 32849781
48DMDNM_004006.2(DMD): c.4315A> T (p.Arg1439Ter)SNVPathogenicrs794727550GRCh37Chr X, 32408217: 32408217
49DMDNM_004006.2(DMD): c.4523delT (p.Leu1508Cysfs)deletionPathogenicrs794727567GRCh37Chr X, 32404578: 32404578
50DMDNM_004006.2(DMD): c.4675-2A> GSNVPathogenicrs794727575GRCh37Chr X, 32398799: 32398799
51DMDNM_004006.2(DMD): c.5697delA (p.Lys1899Asnfs)deletionPathogenicrs794727661GRCh37Chr X, 32361293: 32361293
52DMDNM_004006.2(DMD): c.5868G> A (p.Trp1956Ter)SNVPathogenicrs794727666GRCh37Chr X, 32360271: 32360271
53DMDNM_004006.2(DMD): c.6238delC (p.Gln2080Serfs)deletionPathogenicrs794727672GRCh37Chr X, 32305698: 32305698
54DMDNM_004006.2(DMD): c.6673_6674insGTTT (p.Leu2225Cysfs)insertionPathogenicrs797044743GRCh37Chr X, 31950285: 31950286
55DMDNM_004006.2(DMD): c.6982A> T (p.Lys2328Ter)SNVPathogenicrs754896795GRCh37Chr X, 31893421: 31893421
56DMDNM_004006.2(DMD): c.291dupT (p.Asp98Terfs)duplicationPathogenicrs797044756GRCh37Chr X, 32841478: 32841478
57DMDNM_004006.2(DMD): c.7247dupT (p.Leu2416Phefs)duplicationPathogenicrs797044764GRCh37Chr X, 31838154: 31838154
58DMDNM_004006.2(DMD): c.7295_7296delCC (p.Thr2432Asnfs)deletionPathogenicrs794727746GRCh37Chr X, 31838105: 31838106
59DMDNM_004006.2(DMD): c.7444delC (p.Thr2483Profs)deletionPathogenicrs794727749GRCh37Chr X, 31792175: 31792175
60DMDNM_004006.2(DMD): c.8184delC (p.Lys2729Argfs)deletionPathogenicrs794727763GRCh37Chr X, 31645823: 31645823
61DMDNM_004006.2(DMD): c.8656C> T (p.Gln2886Ter)SNVPathogenicrs201361100GRCh37Chr X, 31497112: 31497112
62DMDNM_004006.2(DMD): c.8669-2A> CSNVPathogenicrs794727770GRCh37Chr X, 31496493: 31496493
63DMDNM_004006.2(DMD): c.415_428delATTCTCCTGAGCTG (p.Ile139Glyfs)deletionPathogenicrs794727795GRCh37Chr X, 32834687: 32834700
64DMDNM_004006.2(DMD): c.9216C> G (p.Tyr3072Ter)SNVPathogenicrs794727820GRCh37Chr X, 31341723: 31341723
65DMDNM_004006.2(DMD): c.9978C> G (p.Tyr3326Ter)SNVPathogenicrs794727832GRCh37Chr X, 31198595: 31198595
66DMDNM_004006.2(DMD): c.565C> T (p.Gln189Ter)SNVPathogenicrs794727861GRCh37Chr X, 32827694: 32827694
67DMDNM_004006.2(DMD): c.547dupT (p.Trp183Leufs)duplicationPathogenicrs796065333GRCh38Chr X, 32809595: 32809595
68DMDNM_004006.2(DMD): c.627delA (p.Ile209Metfs)deletionPathogenicrs794727862GRCh37Chr X, 32827632: 32827632
69DMDNM_004006.2(DMD): c.572C> G (p.Ser191Ter)SNVPathogenicrs794727863GRCh37Chr X, 32827687: 32827687
70DMDNM_004006.2(DMD): c.10554-2A> GSNVPathogenicrs794727890GRCh37Chr X, 31165637: 31165637
71DMDNM_004006.2(DMD): c.5602_5605delAGAA (p.Arg1868Glufs)deletionPathogenicrs863225003GRCh37Chr X, 32361385: 32361388
72DMDNM_004006.2(DMD): c.6611dupA (p.Arg2205Glufs)duplicationPathogenicrs863225007GRCh38Chr X, 31968342: 31968342
73DMDNM_004006.2(DMD): c.8038C> T (p.Arg2680Ter)SNVPathogenicrs863225011GRCh37Chr X, 31645969: 31645969
74DMDNM_004006.2(DMD): c.31+36947G> ASNVPathogenicrs886042106GRCh37Chr X, 33192452: 33192452
75DMDNM_004006.2(DMD): c.5089C> T (p.Gln1697Ter)SNVPathogenicrs886042347GRCh37Chr X, 32382764: 32382764
76DMDNM_004006.2(DMD): c.2603delG (p.Ser868Ilefs)deletionPathogenicrs886042348GRCh37Chr X, 32509413: 32509413
77DMDNM_004006.2(DMD): c.2512C> T (p.Gln838Ter)SNVPathogenicrs886042351GRCh37Chr X, 32509504: 32509504
78DMDNM_004006.2(DMD): c.8111_8112insTTGCCTG (p.Trp2704Cysfs)insertionPathogenicrs886042373GRCh37Chr X, 31645895: 31645896
79DMDNM_004006.2(DMD): c.2316_2317delGA (p.Lys773Valfs)deletionPathogenicrs886042437GRCh37Chr X, 32519935: 32519936
80DMDNM_004006.2(DMD): c.10477C> T (p.Gln3493Ter)SNVPathogenicrs886042495GRCh37Chr X, 31187636: 31187636
81DMDNM_004006.2(DMD): c.1417A> T (p.Lys473Ter)SNVPathogenicrs886042499GRCh37Chr X, 32632485: 32632485
82DMDNM_004006.2(DMD): c.93+1G> ASNVPathogenicrs886042604GRCh37Chr X, 33038255: 33038255
83DMDNM_004006.2(DMD): c.10279C> T (p.Gln3427Ter)SNVPathogenicrs886042691GRCh37Chr X, 31191705: 31191705
84DMDNM_004006.2(DMD): c.5140G> T (p.Glu1714Ter)SNVPathogenicrs886042747GRCh37Chr X, 32382713: 32382713
85DMDNM_004006.2(DMD): c.1047dupA (p.Glu350Argfs)duplicationPathogenicGRCh38Chr X, 32645066: 32645066
86DMDNM_004006.2(DMD): c.10101_10103delAGA (p.Glu3367del)deletionPathogenicrs886042840GRCh37Chr X, 31196906: 31196908
87DMDNM_004006.2(DMD): c.319dupA (p.Thr107Asnfs)duplicationPathogenicGRCh37Chr X, 32841450: 32841450
88DMDNM_004006.2(DMD): c.4550_4556delCTGAAGT (p.Ser1517Trpfs)deletionPathogenicrs886043348GRCh37Chr X, 32404545: 32404551
89DMDNM_004006.2(DMD): c.4174C> T (p.Gln1392Ter)SNVPathogenicrs886043496GRCh37Chr X, 32429928: 32429928
90DMDNM_004006.2(DMD): c.1956delT (p.Asp652Glufs)deletionPathogenicrs886043640GRCh37Chr X, 32583855: 32583855
91DMDNM_004006.2(DMD): c.2052_2053delAG (p.Val685Asnfs)deletionPathogenicrs886043699GRCh38Chr X, 32545274: 32545275
92DMDNM_004006.2(DMD): c.5360dupA (p.Asn1787Lysfs)duplicationPathogenicGRCh37Chr X, 32366611: 32366611
93DMDNM_004006.2(DMD): c.10572T> A (p.Tyr3524Ter)SNVPathogenicrs886043817GRCh37Chr X, 31165617: 31165617
94DMDNM_004006.2(DMD): c.186+2T> ASNVPathogenicrs886043822GRCh37Chr X, 32867843: 32867843
95DMDNM_004006.2(DMD): c.10651_10652insCC (p.Gln3551Profs)insertionPathogenicrs886044325GRCh37Chr X, 31165537: 31165538
96DMDNM_004006.2(DMD): c.3413G> A (p.Trp1138Ter)SNVPathogenicrs886044406GRCh37Chr X, 32481575: 32481575
97DMDNM_004006.2(DMD): c.358-1G> ASNVPathogenicrs886044582GRCh37Chr X, 32834758: 32834758
98DMDNM_004006.2(DMD): c.9G> A (p.Trp3Ter)SNVPathogenicrs398122853GRCh37Chr X, 33229421: 33229421
99DMDNM_004006.2(DMD): c.10033C> T (p.Arg3345Ter)SNVPathogenicrs398123827GRCh37Chr X, 31198540: 31198540
100DMDNM_004006.2(DMD): c.10086+1G> ASNVPathogenicrs398123828GRCh37Chr X, 31198486: 31198486
101DMDNM_004006.2(DMD): c.1012G> T (p.Glu338Ter)SNVPathogenicrs398123830GRCh37Chr X, 32663218: 32663218
102DMDNM_004006.2(DMD): c.10171C> T (p.Arg3391Ter)SNVPathogenicrs398123832GRCh37Chr X, 31196838: 31196838
103DMDNM_004019.2(DMD): c.1020G> A (p.Thr340=)SNVPathogenicrs398123834GRCh37Chr X, 31196785: 31196785
104DMDNM_004006.2(DMD): c.10258dupT (p.Ser3420Phefs)duplicationPathogenicrs398123835GRCh37Chr X, 31196053: 31196053
105DMDNM_004006.2(DMD): c.10446_10447delCT (p.Ser3483Profs)deletionPathogenicrs398123837GRCh37Chr X, 31187666: 31187667
106DMDNM_004006.2(DMD): c.10454delT (p.Leu3485Argfs)deletionPathogenicrs398123839GRCh37Chr X, 31187659: 31187659
107DMDNM_004006.2(DMD): c.1048G> T (p.Glu350Ter)SNVPathogenicrs398123840GRCh37Chr X, 32663182: 32663182
108DMDNM_004006.2(DMD): c.10625delC (p.Pro3542Leufs)deletionPathogenicrs398123844GRCh37Chr X, 31165564: 31165564
109DMDNM_004006.2(DMD): c.1261C> T (p.Gln421Ter)SNVPathogenicrs398123852GRCh37Chr X, 32662319: 32662319
110DMDNM_004006.2(DMD): c.1306dupG (p.Val436Glyfs)duplicationPathogenicrs398123854GRCh37Chr X, 32662274: 32662274
111DMDNM_004006.2(DMD): c.1332-9A> GSNVPathogenicrs72468700GRCh37Chr X, 32632579: 32632579
112DMDNM_004006.2(DMD): c.1341_1342dupAG (p.Val448Glufs)duplicationPathogenicrs398123856GRCh37Chr X, 32632560: 32632561
113DMDNM_004006.2(DMD): c.1371delG (p.Glu459Serfs)deletionPathogenicrs398123857GRCh37Chr X, 32632531: 32632531
114DMDNM_004006.2(DMD): c.137_138dupAT (p.Gly47Metfs)duplicationPathogenicrs398123859GRCh37Chr X, 32867893: 32867894
115DMDNM_004006.2(DMD): c.1465C> T (p.Gln489Ter)SNVPathogenicrs398123861GRCh37Chr X, 32632437: 32632437
116DMDNM_004006.2(DMD): c.1482+1G> TSNVPathogenicrs398123862GRCh37Chr X, 32632419: 32632419
117DMDNM_004006.2(DMD): c.1529_1530delTC (p.Leu510Hisfs)deletionPathogenicrs398123863GRCh37Chr X, 32613946: 32613947
118DMDNM_004006.2(DMD): c.1615C> T (p.Arg539Ter)SNVPathogenicrs398123865GRCh37Chr X, 32591951: 32591951
119DMDNM_004006.2(DMD): c.1886C> A (p.Ser629Ter)SNVPathogenicrs398123867GRCh37Chr X, 32583925: 32583925
120DMDNM_004006.2(DMD): c.1990C> T (p.Gln664Ter)SNVPathogenicrs398123870GRCh37Chr X, 32583821: 32583821
121DMDNM_004006.2(DMD): c.2032C> T (p.Gln678Ter)SNVPathogenicrs398123872GRCh37Chr X, 32563412: 32563412
122DMDNM_004006.2(DMD): c.2125delC (p.Gln709Lysfs)deletionPathogenicrs398123875GRCh37Chr X, 32563319: 32563319
123DMDNM_004006.2(DMD): c.2294_2297delCCAT (p.Ala765Glufs)deletionPathogenicrs398123882GRCh37Chr X, 32519955: 32519958
124DMDNM_004006.2(DMD): c.2332C> T (p.Gln778Ter)SNVPathogenicrs398123883GRCh37Chr X, 32519920: 32519920
125DMDNM_004006.2(DMD): c.2380+1G> CSNVPathogenicrs398123884GRCh37Chr X, 32519871: 32519871
126DMDNM_004006.2(DMD): c.2381-1G> TSNVPathogenicrs398123887GRCh37Chr X, 32509636: 32509636
127DMDNM_004006.2(DMD): c.2419C> T (p.Gln807Ter)SNVPathogenicrs398123888GRCh37Chr X, 32509597: 32509597
128DMDNM_004006.2(DMD): c.2547delT (p.Glu850Lysfs)deletionPathogenicrs398123895GRCh37Chr X, 32509469: 32509469
129DMDNM_004006.2(DMD): c.2650C> T (p.Gln884Ter)SNVPathogenicrs398123903GRCh37Chr X, 32503189: 32503189
130DMDNM_004006.2(DMD): c.2804-1G> ASNVPathogenicrs398123909GRCh37Chr X, 32490427: 32490427
131DMDNM_004006.2(DMD): c.2816T> A (p.Leu939Ter)SNVPathogenicrs398123910GRCh37Chr X, 32490414: 32490414
132DMDNM_004006.2(DMD): c.28delT (p.Cys10Valfs)deletionPathogenicrs398123913GRCh37Chr X, 33229402: 33229402
133DMDNM_004006.2(DMD): c.31+1G> TSNVPathogenicrs398123923GRCh37Chr X, 33229398: 33229398
134DMDNM_004006.2(DMD): c.3151C> T (p.Arg1051Ter)SNVPathogenicrs398123929GRCh37Chr X, 32486626: 32486626
135DMDNM_004006.2(DMD): c.3276+1G> ASNVPathogenicrs398123934GRCh37Chr X, 32482702: 32482702
136DMDNM_004006.2(DMD): c.3295C> T (p.Gln1099Ter)SNVPathogenicrs398123935GRCh37Chr X, 32481693: 32481693
137DMDNM_004006.2(DMD): c.336G> A (p.Trp112Ter)SNVPathogenicrs398123936GRCh37Chr X, 32841433: 32841433
138DMDNM_004006.2(DMD): c.3432+1G> ASNVPathogenicrs398123937GRCh37Chr X, 32481555: 32481555
139DMDNM_004006.2(DMD): c.3580C> T (p.Gln1194Ter)SNVPathogenicrs398123942GRCh37Chr X, 32472802: 32472802
140DMDNM_004006.2(DMD): c.3603+2T> ASNVPathogenicrs146071084GRCh37Chr X, 32472777: 32472777
141DMDNM_004006.2(DMD): c.3639dupA (p.Val1214Serfs)duplicationPathogenicrs398123943GRCh37Chr X, 32466720: 32466720
142DMDNM_004006.2(DMD): c.3747delG (p.Trp1249Cysfs)deletionPathogenicrs398123945GRCh37Chr X, 32466612: 32466612
143DMDNM_004006.2(DMD): c.3779_3785delCTTTGGAinsGG (p.Thr1260Argfs)indelPathogenicrs398123946GRCh37Chr X, 32466574: 32466580
144DMDNM_004006.2(DMD): c.4117C> T (p.Gln1373Ter)SNVPathogenicrs398123948GRCh37Chr X, 32429985: 32429985
145DMDNM_004006.2(DMD): c.412_413delAA (p.Lys138Aspfs)deletionPathogenicrs398123949GRCh37Chr X, 32834702: 32834703
146DMDNM_004006.2(DMD): c.434G> C (p.Arg145Pro)SNVPathogenicrs398123952GRCh37Chr X, 32834681: 32834681
147DMDNM_004006.2(DMD): c.4471_4472delAA (p.Lys1491Glufs)deletionPathogenicrs398123957GRCh37Chr X, 32407664: 32407665
148DMDNM_004006.2(DMD): c.4534_4535delCT (p.Leu1512Glufs)deletionPathogenicrs398123961GRCh37Chr X, 32404566: 32404567
149DMDNM_004006.2(DMD): c.4545_4549delGAAGT (p.Lys1516Terfs)deletionPathogenicrs398123962GRCh37Chr X, 32404552: 32404556
150DMDNM_004006.2(DMD): c.4843A> T (p.Lys1615Ter)SNVPathogenicrs398123969GRCh37Chr X, 32398629: 32398629
151DMDNM_004006.2(DMD): c.5124_5127delGAAA (p.Lys1708Asnfs)deletionPathogenicrs398123979GRCh37Chr X, 32382726: 32382729
152DMDNM_004006.2(DMD): c.5287C> T (p.Arg1763Ter)SNVPathogenicrs398123981GRCh37Chr X, 32380943: 32380943
153DMDNM_004006.2(DMD): c.5530C> T (p.Arg1844Ter)SNVPathogenicrs1064325GRCh37Chr X, 32364116: 32364116
154DMDNM_004006.2(DMD): c.5640T> A (p.Tyr1880Ter)SNVPathogenicrs398123993GRCh37Chr X, 32361350: 32361350
155DMDNM_004006.2(DMD): c.583C> T (p.Arg195Ter)SNVPathogenicrs398123999GRCh37Chr X, 32827676: 32827676
156DMDNM_004006.2(DMD): c.5938G> T (p.Glu1980Ter)SNVPathogenicrs398124001GRCh37Chr X, 32328378: 32328378
157DMDNM_004006.2(DMD): c.6000T> A (p.Tyr2000Ter)SNVPathogenicrs398124002GRCh37Chr X, 32328316: 32328316
158DMDNM_004006.2(DMD): c.6072T> A (p.Cys2024Ter)SNVPathogenicrs373804251GRCh37Chr X, 32328244: 32328244
159DMDNM_004006.2(DMD): c.615T> A (p.Tyr205Ter)SNVPathogenicrs398124004GRCh37Chr X, 32827644: 32827644
160DMDNM_004006.2(DMD): c.6182delC (p.Ala2061Glufs)deletionPathogenicrs398124005GRCh37Chr X, 32305754: 32305754
161DMDNM_004006.2(DMD): c.649+1G> ASNVPathogenicrs398124032GRCh37Chr X, 32827609: 32827609
162DMDNM_004006.2(DMD): c.676_678delAAG (p.Lys226del)deletionPathogenicrs398124034GRCh37Chr X, 32717382: 32717384
163DMDNM_004006.2(DMD): c.6906G> A (p.Trp2302Ter)SNVPathogenicrs398124036GRCh37Chr X, 31947719: 31947719
164DMDNM_004006.2(DMD): c.7189C> T (p.Gln2397Ter)SNVPathogenicrs398124042GRCh37Chr X, 31854846: 31854846
165DMDNM_004006.2(DMD): c.7309+1G> ASNVPathogenicrs398124044GRCh37Chr X, 31838091: 31838091
166DMDNM_004006.2(DMD): c.7657C> T (p.Arg2553Ter)SNVPathogenicrs398124050GRCh37Chr X, 31747751: 31747751
167DMDNM_004006.2(DMD): c.7682G> A (p.Trp2561Ter)SNVPathogenicrs398124052GRCh37Chr X, 31697682: 31697682
168DMDNM_004006.2(DMD): c.7683G> A (p.Trp2561Ter)SNVPathogenicrs398124053GRCh37Chr X, 31697681: 31697681
169DMDNM_004006.2(DMD): c.7894C> T (p.Gln2632Ter)SNVPathogenicrs398124058GRCh37Chr X, 31676240: 31676240
170DMDNM_004006.2(DMD): c.8064_8065delTA (p.His2688Glnfs)deletionPathogenicrs398124060GRCh37Chr X, 31645942: 31645943
171DMDNM_004006.2(DMD): c.8069T> G (p.Leu2690Ter)SNVPathogenicrs398124061GRCh37Chr X, 31645938: 31645938
172DMDNM_004006.2(DMD): c.8374_8375delAA (p.Lys2792Valfs)deletionPathogenicrs398124070GRCh37Chr X, 31525413: 31525414
173DMDNM_004006.2(DMD): c.8608C> T (p.Arg2870Ter)SNVPathogenicrs398124074GRCh37Chr X, 31497160: 31497160
174DMDNM_004006.2(DMD): c.8652_8653delCT (p.Tyr2885Profs)deletionPathogenicrs398124075GRCh37Chr X, 31497115: 31497116
175DMDNM_004006.2(DMD): c.8912_8913delTC (p.Leu2971Profs)deletionPathogenicrs398124078GRCh37Chr X, 31496247: 31496248
176DMDNM_004006.2(DMD): c.9125delA (p.His3042Profs)deletionPathogenicrs398124080GRCh37Chr X, 31366711: 31366711
177DMDNM_004006.2(DMD): c.9225-647A> GSNVPathogenicrs398124091GRCh37Chr X, 31279780: 31279780
178DMDNM_004006.2(DMD): c.9337C> T (p.Arg3113Ter)SNVPathogenicrs398124092GRCh37Chr X, 31241188: 31241188
179DMDNM_004006.2(DMD): c.9361+1G> ASNVPathogenicrs398124094GRCh37Chr X, 31241163: 31241163
180DMDNM_004006.2(DMD): c.9361+1G> CSNVPathogenicrs398124094GRCh37Chr X, 31241163: 31241163
181DMDNM_004006.2(DMD): c.9564-1G> ASNVPathogenicrs398124096GRCh37Chr X, 31224785: 31224785
182DMDNM_004006.2(DMD): c.9650-2A> GSNVPathogenicrs398124100GRCh37Chr X, 31222237: 31222237
183DMDNM_004006.2(DMD): c.9862G> T (p.Glu3288Ter)SNVPathogenicrs398124106GRCh37Chr X, 31200967: 31200967

Expression for genes affiliated with Becker Muscular Dystrophy

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Becker Muscular Dystrophy patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MYH3myosin, heavy chain 3, skeletal muscle, embryonicSkeletal Muscle+4.140.000

Search GEO for disease gene expression data for Becker Muscular Dystrophy.

GO Terms for genes affiliated with Becker Muscular Dystrophy

About this section

Cellular components related to Becker Muscular Dystrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1filopodium membraneGO:003152710.6DMD, UTRN
2cell-substrate junctionGO:003005510.6DMD, VCL
3costamereGO:004303410.6DMD, VCL
4membrane raftGO:004512110.0DMD, NOS1, SGCA
5synapseGO:00452029.9DMD, NOS1, UTRN
6protein complexGO:00432349.7DMD, NOS1, UTRN, VCL
7dystrophin-associated glycoprotein complexGO:00160109.6DMD, FKRP, SGCA, UTRN
8cytoskeletonGO:00058569.3DMD, NOS1, SGCA, UTRN, VCL
9T-tubuleGO:00303159.2DYSF, NOS1
10sarcolemmaGO:00423837.7DMD, DYSF, FKRP, LAMA2, NOS1, SGCA

Biological processes related to Becker Muscular Dystrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1regulation of ryanodine-sensitive calcium-release channel activityGO:006031410.2DMD, NOS1
2skeletal muscle tissue developmentGO:00075199.7DMD, MYF6
3muscle organ developmentGO:00075179.3DMD, LAMA2, SGCA, UTRN
4muscle contractionGO:00069369.1DYSF, SGCA, UTRN, VCL

Molecular functions related to Becker Muscular Dystrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dystroglycan bindingGO:000216210.1DMD, VCL
2vinculin bindingGO:00171669.9DMD, UTRN
3actin bindingGO:00037799.8DMD, UTRN, VCL

Sources for Becker Muscular Dystrophy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet